Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020
John W. Ostrominski(Brigham and Women's Hospital), Muthiah Vaduganathan(Brigham and Women's Hospital), Javed Butler(Jackson Memorial Hospital), Jamie S. Hirsch(Donald & Barbara Zucker School of Medicine at Hofstra/Northwell), Suzanne V. Arnold(Saint Luke's Health System), Mikhail Kosiborod(AstraZeneca (Brazil)), B.M.K. Donato(Boehringer Ingelheim (United States)), Gregg C. Fonarow(UCLA Medical Center), Jonathan J. Woolley, Eric B. Collins, Christina M. Parrinello, Swetha Palli(Boehringer Ingelheim (United States)), Thomas M. O’Connell(Indiana University School of Medicine)
Cited by 248
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction
|Circulation|2010|4.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2023|2.2k